UA130250C2 - Рідкий фармацевтичний склад та композиція на основі антитіла до fgfr2 - Google Patents
Рідкий фармацевтичний склад та композиція на основі антитіла до fgfr2Info
- Publication number
- UA130250C2 UA130250C2 UAA202102307A UAA202102307A UA130250C2 UA 130250 C2 UA130250 C2 UA 130250C2 UA A202102307 A UAA202102307 A UA A202102307A UA A202102307 A UAA202102307 A UA A202102307A UA 130250 C2 UA130250 C2 UA 130250C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antibody
- composition
- esek2
- rgo
- tpg
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862741772P | 2018-10-05 | 2018-10-05 | |
| PCT/US2019/054684 WO2020072896A1 (en) | 2018-10-05 | 2019-10-04 | Anti-fgfr2 antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA130250C2 true UA130250C2 (uk) | 2025-12-31 |
Family
ID=68343457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA202102307A UA130250C2 (uk) | 2018-10-05 | 2019-10-04 | Рідкий фармацевтичний склад та композиція на основі антитіла до fgfr2 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220010020A1 (enExample) |
| EP (1) | EP3860563A1 (enExample) |
| JP (2) | JP7595567B2 (enExample) |
| KR (1) | KR20210074286A (enExample) |
| CN (1) | CN112804989A (enExample) |
| AU (1) | AU2019355995B2 (enExample) |
| BR (1) | BR112021005204A2 (enExample) |
| CA (1) | CA3112215A1 (enExample) |
| CO (1) | CO2021004985A2 (enExample) |
| CR (1) | CR20210217A (enExample) |
| EA (1) | EA202190878A1 (enExample) |
| EC (1) | ECSP21031139A (enExample) |
| IL (1) | IL281976A (enExample) |
| MX (1) | MX2021003766A (enExample) |
| MY (1) | MY208925A (enExample) |
| PE (1) | PE20211213A1 (enExample) |
| PH (1) | PH12021550670A1 (enExample) |
| SG (1) | SG11202102875YA (enExample) |
| UA (1) | UA130250C2 (enExample) |
| WO (1) | WO2020072896A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| JP2024501565A (ja) * | 2020-12-29 | 2024-01-12 | 深▲せん▼福沃薬業有限公司 | 抗ｆｇｆｒ２抗体およびその使用 |
| TW202342527A (zh) * | 2022-02-25 | 2023-11-01 | 美商安進公司 | 鱗狀非小細胞肺癌之治療 |
| CN119110806A (zh) * | 2022-03-28 | 2024-12-10 | 杭州中美华东制药有限公司 | 新型抗fgfr2抗体 |
| CN121039158A (zh) * | 2023-03-31 | 2025-11-28 | 杭州中美华东制药有限公司 | 新型抗fgfr2抗体 |
| WO2025067442A1 (zh) * | 2023-09-28 | 2025-04-03 | 南京维立志博生物科技股份有限公司 | 抗fgfr2抗体和包含其的多特异性结合分子 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT WITH ANTIBODY COMPOSITION |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| AU2008208288B2 (en) | 2007-01-24 | 2014-04-03 | Kyowa Kirin Co., Ltd. | Genetically recombinant antibody composition having enhanced effector activity |
| HUE035700T2 (en) | 2008-11-07 | 2018-05-28 | Galaxy Biotech Llc | Monoclonal antibodies to Fibroblast Growth Factor receptor 2 |
| KR102516152B1 (ko) | 2013-08-01 | 2023-03-31 | 파이브 프라임 테라퓨틱스, 인크. | 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체 |
| MX2018006181A (es) | 2015-11-23 | 2018-09-24 | Five Prime Therapeutics Inc | Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer. |
-
2019
- 2019-10-04 PE PE2021000414A patent/PE20211213A1/es unknown
- 2019-10-04 SG SG11202102875YA patent/SG11202102875YA/en unknown
- 2019-10-04 CN CN201980064961.XA patent/CN112804989A/zh active Pending
- 2019-10-04 MX MX2021003766A patent/MX2021003766A/es unknown
- 2019-10-04 JP JP2021517575A patent/JP7595567B2/ja active Active
- 2019-10-04 US US17/282,589 patent/US20220010020A1/en active Pending
- 2019-10-04 AU AU2019355995A patent/AU2019355995B2/en active Active
- 2019-10-04 UA UAA202102307A patent/UA130250C2/uk unknown
- 2019-10-04 KR KR1020217009515A patent/KR20210074286A/ko not_active Ceased
- 2019-10-04 BR BR112021005204-6A patent/BR112021005204A2/pt unknown
- 2019-10-04 EP EP19794304.6A patent/EP3860563A1/en active Pending
- 2019-10-04 EA EA202190878A patent/EA202190878A1/ru unknown
- 2019-10-04 MY MYPI2021001632A patent/MY208925A/en unknown
- 2019-10-04 WO PCT/US2019/054684 patent/WO2020072896A1/en not_active Ceased
- 2019-10-04 CA CA3112215A patent/CA3112215A1/en active Pending
- 2019-10-04 CR CR20210217A patent/CR20210217A/es unknown
-
2021
- 2021-03-25 PH PH12021550670A patent/PH12021550670A1/en unknown
- 2021-04-01 IL IL281976A patent/IL281976A/en unknown
- 2021-04-19 CO CONC2021/0004985A patent/CO2021004985A2/es unknown
- 2021-05-03 EC ECSENADI202131139A patent/ECSP21031139A/es unknown
-
2024
- 2024-06-19 JP JP2024098544A patent/JP2024138284A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021003766A (es) | 2021-05-27 |
| PE20211213A1 (es) | 2021-07-05 |
| AU2019355995B2 (en) | 2026-04-09 |
| ECSP21031139A (es) | 2021-06-30 |
| JP2024138284A (ja) | 2024-10-08 |
| KR20210074286A (ko) | 2021-06-21 |
| SG11202102875YA (en) | 2021-04-29 |
| CA3112215A1 (en) | 2020-04-09 |
| MY208925A (en) | 2025-06-11 |
| PH12021550670A1 (en) | 2022-01-03 |
| WO2020072896A1 (en) | 2020-04-09 |
| EA202190878A1 (ru) | 2021-07-02 |
| JP7595567B2 (ja) | 2024-12-06 |
| CO2021004985A2 (es) | 2021-04-30 |
| CN112804989A (zh) | 2021-05-14 |
| US20220010020A1 (en) | 2022-01-13 |
| IL281976A (en) | 2021-05-31 |
| CR20210217A (es) | 2021-06-18 |
| EP3860563A1 (en) | 2021-08-11 |
| JP2022503886A (ja) | 2022-01-12 |
| AU2019355995A1 (en) | 2021-04-08 |
| BR112021005204A2 (pt) | 2021-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA130250C2 (uk) | Рідкий фармацевтичний склад та композиція на основі антитіла до fgfr2 | |
| US10913797B2 (en) | Anti-PD-1 antibodies and therapeutic uses thereof | |
| EP3883966B1 (en) | Humanized anti-human-pd-1 antibody | |
| EP3423495B1 (en) | Antibodies specific to human poliovirus receptor (pvr) | |
| TWI791422B (zh) | 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合 | |
| ES2719103T3 (es) | Anticuerpos anti-FGFR2IIIB afucosilados | |
| US20220017601A1 (en) | TGF-beta RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| JP2019503674A (ja) | 抗ｌａｇ３抗体および抗原結合性フラグメント | |
| CN109715667A (zh) | 抗-gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子及其用途 | |
| BR112019021182A2 (pt) | Agentes de anticorpo anti-cd33 | |
| TW201740976A (zh) | 包含抗pd-l1及抗ctla-4抗體之共調配物之組合物 | |
| KR20160038892A (ko) | 암의 치료 및/또는 예방용 의약 조성물 | |
| BR112020003362A2 (pt) | antagonistas de tim-3 para o tratamento e diagnóstico de cânceres | |
| RS65630B1 (sr) | Farmaceutska kompozicija za upotrebu u lečenju ili prevenciji bolesti povezane sa c5 | |
| CN109069639A (zh) | Gitr抗体、方法及用途 | |
| WO2020007368A1 (zh) | 低adcc/cdc功能性单抗及其制备方法与应用 | |
| EP3848049A1 (en) | Anti-tim3 antibody pharmaceutical composition and use thereof | |
| CN117355331A (zh) | 抗Siglec组合物及其用途 | |
| TW202245839A (zh) | Dr5結合多肽之調配物 | |
| US20230084382A1 (en) | Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor | |
| US20220169746A1 (en) | Antibodies to neoantigens and uses thereof | |
| WO2025168052A1 (en) | Nkg2a/cd94-targeting antibodies and uses thereof | |
| EP3444272A1 (en) | Treatment of ck8 positive cancers in relation with k-ras gene status | |
| EA049555B1 (ru) | Составы на основе антитела к fgfr2 | |
| EP4548929A1 (en) | Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof |